Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
Clinical trial NCT02393625 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02393625
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-27
- Primary completion
- 2027-04-09
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.